Santos Edgardo S, Kharfan-Dabaja Mohamed A
Tulane University Health Sciences Center, Division of Hematology-Medical Oncology, 1430 Tulane Avenue, SL-78 New Orleans, LA 70112, USA.
Expert Rev Anticancer Ther. 2006 Oct;6(10):1483-501. doi: 10.1586/14737140.6.10.1483.
Recent advances in the understanding of the molecular and biological aspects of multiple myeloma have opened new horizons in the management and treatment of this hitherto incurable disease. With better understanding of the pathobiological 'web' responsible for triggering plasma cells to develop into myeloma, scientists have been able to develop therapeutic strategies that target not only the myeloma cell, but its microenvironment as well. This article will review novel agents commonly used to treat multiple myeloma, either alone or in combination. The role of these agents as induction therapy in newly diagnosed, relapsed and/or refractory disease will also be evaluated. Finally, an overview of novel therapies moving from the bench to the bedside will be provided.
在多发性骨髓瘤分子和生物学方面的理解上取得的最新进展，为这种迄今为止无法治愈的疾病的管理和治疗开辟了新的视野。随着对导致浆细胞发展为骨髓瘤的病理生物学“网络”有了更深入的了解，科学家们已经能够制定不仅针对骨髓瘤细胞，而且针对其微环境的治疗策略。本文将综述单独或联合使用的常用于治疗多发性骨髓瘤的新型药物。还将评估这些药物在新诊断、复发和/或难治性疾病中作为诱导治疗的作用。最后，将概述从实验室走向临床的新型疗法。
